Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide and Everolimus in Thyroid Cancer
NCT01270321Phase 2Completed
- Sponsor
- Emory University
- Start
- Nov 2010
- Primary completion
- Feb 2019
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in thyroid cancer comparing Everolimus alone, Pasireotide alone and Everolimus + Pasireotide (3 arms). Primary endpoint: Objective Response Rate at 1 year. Started Nov 2010; status: completed.
02
Drugs
pasireotide LAReverolimus
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on NCT01270321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01270321.